Advertisement
As of 02:45PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 101.43 |
| Open | 101.55 |
| Bid | 101.91 x 1200 |
| Ask | 101.92 x 800 |
| Day's Range | 100.86 - 102.30 |
| 52 Week Range | 61.16 - 105.69 |
| Volume | |
| Avg. Volume | 4,814,263 |
| Market Cap | 466.63B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 41.58 |
| EPS (TTM) | 2.45 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.03 (1.02%) |
| Ex-Dividend Date | Aug 18, 2023 |
| 1y Target Est | 103.96 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-27% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for NVO
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Novo Nordisk A/SAnalyst Report: Novo Nordisk A/SWith roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.RatingFair ValueEconomic Moat20 hours agoMorningstar
ZacksEmergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
ZacksIs Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
ZacksMerck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.